Inclusion Criteria:

- Males aged 20 years or older.

- Histologically or Cytologically proven diagnosis of prostate cancer for which no
standard therapy is currently considered appropriate

- Documented evidence of metastatic prostate cancer

- Serum testosterone concentration ≤50 ng/dL

- World Health Organisation (WHO) performance status 0 to 1 with no deterioration over
the previous 2 weeks and minimum life expectancy of 12 weeks

Exclusion Criteria:

- History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with
a similar chemical structure or class to AZD3514

- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
swallow the formulated product or previous significant bowel resection that would
preclude adequate absorption of AZD3514

- Inadequate bone marrow reserve or organ function

- Concurrent or recent treatment with certain medications or medical procedures

- Any medically important factors identified from electrocardiogram (ECG) measurements